Brain effects of ALK/ROS1 lung cancer drugs and quality of life
Part of Cancer, Lungs & breathing, Mental health clinical trials.
This study looks at how certain targeted therapy drugs for ALK/ROS1-positive lung cancer may affect thinking, memory, mood, and mental health. It aims to build a special care and research path where patients and researchers work together to understand and manage these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and speak French fluently.
- You are currently taking a targeted therapy drug for ALK/ROS1-positive lung cancer.
- Your doctor has noted you have some problems with thinking, memory, mood, or other brain-related symptoms that might be linked to your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often lorlatinib, a targeted therapy for ALK-positive lung cancer, causes side effects in the brain or nervous system. Researchers hope to find risk factors so doctors can better monitor and manage these effects.
This study looks at how lung cancer and its treatment might affect thinking and memory. If you are having surgery for early-stage lung cancer, you may be asked to complete online questionnaires to help researchers track these changes over time.
This trial tests whether a medication called vortioxetine can help improve memory, focus, and thinking problems caused by lorlatinib, a drug used to treat ALK-positive lung cancer. You would take vortioxetine alongside your current cancer treatment to see if it helps your brain function.
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
This trial studies how radiotherapy affects memory and thinking in adults with certain brain or skull-base tumors. It may help doctors understand who is most likely to have thinking changes and how to monitor or support patients.
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.